ELCC 2017

Exciting current topics in lung cancer 1:33
Exciting current topics in lung cancer
Solange Peters • 5 May 2017
Phase II study of Durvalumab for patients with NSCLC 1:13
Phase II study of Durvalumab for patients with NSCLC
David Gandara • 5 May 2017
Evolving guidelines for molecular testing in lung cancer 1:48
Evolving guidelines for molecular testing in lung cancer
Fred Hirsch • 5 May 2017
Current treatment landscape for neuroendocrine tumors 0:51
Current treatment landscape for neuroendocrine tumors
Keith Kerr • 5 May 2017
Biomarker testing in NSCLC 2:04
Biomarker testing in NSCLC
Keith Kerr • 5 May 2017
The LUME-BioNIS study and its aims 1:29
The LUME-BioNIS study and its aims
Keith Kerr • 5 May 2017
The BIRCH trial data discussed by Dr Peters 1:10
The BIRCH trial data discussed by Dr Peters
Solange Peters • 5 May 2017
The open questions surrounding immunotherapy and targeted therapy in lung cancer 2:29
The open questions surrounding immunotherapy and targeted therapy in lung cancer
Solange Peters • 5 May 2017
Challenges and opportunities for patients with advanced NSCLC 1:46
Challenges and opportunities for patients with advanced NSCLC
Solange Peters • 5 May 2017
Increasing patient access to the latest treatments 2:43
Increasing patient access to the latest treatments
Solange Peters • 5 May 2017
Why is European Lung Cancer Conference so important? 0:47
Why is European Lung Cancer Conference so important?
Solange Peters
Molecular tools for lung cancer therapies 1:15
Molecular tools for lung cancer therapies
Charles Swanton • 5 May 2017
Benefits of targeted therapeutics in Lung Cancer 2:09
Benefits of targeted therapeutics in Lung Cancer
David Carbone • 5 May 2017
Increasing treatment options for NSCLC 2:07
Increasing treatment options for NSCLC
David Gandara • 5 May 2017
Genetic evolution of NSCLC 2:09
Genetic evolution of NSCLC
Charles Swanton • 5 May 2017
NSCLC: identifying patients most likely to relapse 1:35
NSCLC: identifying patients most likely to relapse
Charles Swanton • 5 May 2017
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals